Paid Clinical Trials Meridian

Discover 273 paid clinical trials in Meridian, Idaho. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 273

MyeloMATCHComparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Meridian ID, Boise ID, Nampa ID, Fruitland IDshow 9 more

Code:

NCT06672146

Conditions

Acute Myeloid Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Decitabine and Cedazuridine

Enasidenib

IbrutinibA Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia

Recruiting

PHASE2

Sponsor:

Janssen Research & Development, LLC

Location:

Boise ID, Ogden UT, Eugene OR, Portland ORshow 29 more

Code:

NCT05963074

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Small Lymphocytic Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ibrutinib

Venetoclax

Chemotherapy with Endocrine TherapyEvaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Meridian ID, Boise ID, Nampa ID, Caldwell IDshow 715 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

Lenalidomide & DaratumumabS1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Recruiting

PHASE3

Sponsor:

SWOG Cancer Research Network

Location:

Meridian ID, Boise ID, Nampa ID, Caldwell IDshow 530 more

Code:

NCT04071457

Conditions

Multiple Myeloma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Lenalidomide

Daratumumab/rHuPH20

Selumetinib vs. Carboplatin/VincristineA Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Recruiting

PHASE3

Sponsor:

National Cancer Institute (NCI)

Location:

Boise ID, Spokane WA, Salt Lake City UT, Portland ORshow 104 more

Code:

NCT03871257

Conditions

Low Grade Glioma

Neurofibromatosis Type 1

Visual Pathway Glioma

Eligibility Criteria

Sex: All

Age: 2 - 21

Healthy Volunteers: Not accepted

Interventions

Carboplatin

Magnetic Resonance Imaging

Quality-of-Life Assessment

Questionnaire Administration

Selumetinib Sulfate

Nivolumab, Ipilimumab, CabozantinibTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Recruiting

PHASE2

Sponsor:

National Cancer Institute (NCI)

Location:

Meridian ID, Boise ID, Nampa ID, Caldwell IDshow 368 more

Code:

NCT03866382

Conditions

Bladder Adenocarcinoma

Bladder Clear Cell Adenocarcinoma

Bladder Mixed Adenocarcinoma

Bladder Neuroendocrine Carcinoma

Bladder Small Cell Neuroendocrine Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Bone Scan

Cabozantinib S-malate

Computed Tomography

Echocardiography Test

VilobelimabJUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

Recruiting

PHASE2

Sponsor:

PPD DEVELOPMENT, LP

Location:

Boise ID, Reno NV

Code:

NCT06701682

Conditions

Acute Respiratory Distress Syndrome (ARDS)

ARDS

ARDS (Acute Respiratory Distress Syndrome)

Acute Respiratory Distress Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cohort A: vilobelimab

Cohort A: placebo

RGLS8429A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

Recruiting

PHASE1

Sponsor:

Regulus Therapeutics Inc.

Location:

Boise ID, Chubbuck ID, Idaho Falls ID, Seattle WAshow 23 more

Code:

NCT05521191

Conditions

Autosomal Dominant Polycystic Kidney Disease

ADPKD

Polycystic Kidney, Autosomal Dominant

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

RGLS8429

Placebo

DonanemabA Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Boise ID, Bend OR, Spokane Valley WA, Portland ORshow 172 more

Code:

NCT05026866

Conditions

Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Not accepted

Interventions

Donanemab

Placebo

GalcanezumabA Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Meridian ID, Boise ID, Ammon ID, Logan UTshow 42 more

Code:

NCT04616326

Conditions

Chronic Migraine

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Galcanezumab

Placebo